ARTICLE | Clinical News
Liovel alogliptin/pioglitazone regulatory update
November 7, 2011 8:00 AM UTC
Alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is approved for the indication in Japan as Nesina. Alogliptin was discovered by Syrrx Inc., which was acquired by Takeda in 2005. PPD Inc. (...